News Ajanta Pharma Limited

Equities

AJANTPHARM

INE031B01049

Delayed NSE India S.E. Other stock markets 03:36:21 2024-04-26 am EDT			5-day change	1st Jan Change
2,140 ^INR	+0.00%		+2.62%	+2.70%

Feb. 02	Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit	MT
Jan. 31	Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ex-dividend day for interim dividend	Feb. 07	FA
Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit	Feb. 02	MT
Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024	Jan. 31
Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024	Jan. 31	CI
Ajanta Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 31	CI
Ajanta Pharma Board to Consider Second Interim Dividend for Fiscal 2024	Jan. 25	MT
Ajanta Pharma Limited Provides Earnings Guidance for the Full Year of Fiscal 2024	23-10-31	CI
Transcript : Ajanta Pharma Limited, Q2 2024 Earnings Call, Oct 31, 2023	23-10-31
Ajanta Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-31	CI
Ajanta Pharma Gets US FDA Nod for Topiramate Extended-Release Capsules	23-08-30	MT
Ajanta Pharma Limited Receives Final Approval from US FDA for Topiram Extended Release Capsules	23-08-30	CI
Ex-dividend day for extraordinary dividend	23-08-03	FA
Ex-dividend day for interim dividend	23-08-03	FA
Ajanta Pharma Logs Increase in Fiscal Q1 Consolidated Profit	23-07-28	MT
Transcript : Ajanta Pharma Limited, Q1 2024 Earnings Call, Jul 27, 2023	23-07-27
Ajanta Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-27	CI
Ajanta Pharma Board to Consider Interim Dividend for Fiscal 2024	23-07-24	MT
Ajanta Pharma Limited Confirms the Interim Dividend for the Year Ended 31 March 2023	23-07-18	CI
Ajanta Pharma Gets No Observations After US FDA's Inspection of API Facility in Hyderabad, India	23-06-25	MT
Transcript : Ajanta Pharma Limited, Q4 2023 Earnings Call, May 05, 2023	23-05-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ajanta Pharma Limited

Equities

AJANTPHARM

INE031B01049

Summary

Filters